{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=85",
    "query": {
      "condition": "Phase II",
      "page": 85
    },
    "page_size": 10
  },
  "pagination": {
    "page": 85,
    "page_size": 10,
    "total_count": 21412,
    "total_pages": 2142,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=86&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=84&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T04:00:36.455Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05297578",
      "title": "Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Vaccines"
      ],
      "interventions": [
        {
          "name": "24-Valent Pneumococcal Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 20-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxcyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2022-06-15",
      "completion_date": "2023-02-15",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • DeLand, Florida • Hollywood, Florida + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05297578"
    },
    {
      "nct_id": "NCT03770689",
      "title": "Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Peposertib 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Peposertib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Peposertib 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Peposertib 250 mg",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy (RT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2019-03-20",
      "completion_date": "2022-02-21",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Great Neck, New York + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03770689"
    },
    {
      "nct_id": "NCT03682289",
      "title": "Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Locally Advanced Pancreatic Cancer",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Metastatic Pancreatic Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Renal Cell Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Renal Cell Cancer",
        "Endometrial Cancer",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rahul Aggarwal",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2019-01-17",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 3,
      "location_summary": "Duarte, California • San Francisco, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682289"
    },
    {
      "nct_id": "NCT06661291",
      "title": "Pip Care to Improve Surgical Patient Outcomes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Abdominal Surgery"
      ],
      "interventions": [
        {
          "name": "Pip Care Digital Health Platform",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care Protocol",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2025-10-13",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 8,
      "location_summary": "New Castle, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "New Castle",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06661291"
    },
    {
      "nct_id": "NCT00026091",
      "title": "Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Primary Peritoneal Cavity Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "fenretinide",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 40,
      "start_date": "2001-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-03-25",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026091"
    },
    {
      "nct_id": "NCT02756897",
      "title": "Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2016-07-07",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02756897"
    },
    {
      "nct_id": "NCT01960413",
      "title": "Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)"
      ],
      "interventions": [
        {
          "name": "Montelukast added to Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Placebo added to Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 46,
      "start_date": "2013-11",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01960413"
    },
    {
      "nct_id": "NCT00217282",
      "title": "Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "oxaliplatin, gemcitabine, bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mt. Sinai Medical Center, Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 45,
      "start_date": "2004-06",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2008-05-22",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 1,
      "location_summary": "Miami Beach, Florida",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217282"
    },
    {
      "nct_id": "NCT06150924",
      "title": "Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mineralys Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-12-14",
      "completion_date": "2025-04-23",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 44,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06150924"
    },
    {
      "nct_id": "NCT01619423",
      "title": "A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Metastatic (Stage IV) Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "PledOx (2 µmol/kg)",
          "type": "DRUG"
        },
        {
          "name": "PledOx (5 µmol/kg)",
          "type": "DRUG"
        },
        {
          "name": "PledOx (10 µmol/kg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (0,9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Egetis Therapeutics AB (publ)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2012-09",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-11-16T04:00:36.455Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Kingsport",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01619423"
    }
  ]
}